Andrew J. Muir, MD, MHS Andrew J. Muir, MD, MHS

Andrew J. Muir, MD, MHS

Hepatologist

4.9 out of 5  (151 ratings, 20 reviews)
Duke Health Provider What's this?
Insurance

Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below. Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy

Click to see a list of accepted insurance plansHide accepted insurance plans
Contact
919-684-1817 Office number
919-684-8264
Fax number
Insurance

Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below. Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy

Click to see a list of accepted insurance plansHide accepted insurance plans

Contact
WHERE I PROVIDE CARE
Profile
ABOUT ME

I am proud to serve as the Chief of the Duke Division of Gastroenterology. In addition to my administrative duties, I enjoy my clinical practice focused on the care of patients with liver diseases. I also continue to participate in clinical research that and hope that these studies offer our patients the latest advances and treatment options.

LANGUAGES I SPEAK
English
LEARN MORE ABOUT ME
Training
EDUCATION
MD, Duke University School of Medicine, 1993
RESIDENCY
Internal Medicine, Duke University Medical Center, 1993-1996 (Chief Resident, 1997-1998)
FELLOWSHIP
Gastroenterology, Duke University Medical Center, 1996-1997, 1998-2000
BOARD CERTIFICATION
American Board of Internal Medicine, Gastroenterology
Clinical Focus and Research
MY RESEARCH INTERESTS

We take part in studies of new therapies for patients with liver disease. Through our clinical trials, we can offer patients other treatment options and often earlier access to new therapies. It has been my privilege to take part in many of the studies of new drugs for hepatitis C over the last decade. These treatments are now available in our clinical practice, and we are very comfortable with these new drugs, given our experience in these clinical trials over the last several years. With the progress in hepatitis C, we are now turning our attention to other liver diseases. I have personally started to focus on primary sclerosing cholangitis and cirrhosis.

Ratings and Reviews

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more about our survey process. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Overall provider rating
4.9 out of 5 (151 ratings, 20 reviews)
PATIENT REVIEWS
Patient comments are gathered from our Press Ganey Patient Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
Industry Relationships and Collaborations
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
  • AbbVie
  • Gilead Sciences, Inc.
  • Inovio
  • Merck
  • Portola Pharmaceuticals, Inc.
  • Shire Pharmaceuticals